A Phase 2 Open Label Study to Investigate the Safety and Clinical Activity of Autologous EBV-specific T Cells (CMD-003) for the Treatment of Patients With EBV Positive Lymphomas
Phase of Trial: Phase II
Latest Information Update: 16 Aug 2017
At a glance
- Drugs Baltaleucel-T (Primary)
- Indications Diffuse large B cell lymphoma; Hodgkin's disease; Post-transplant lymphoproliferative disorder
- Focus Therapeutic Use
- Acronyms CIVIC
- Sponsors Cell Medica
- 27 Dec 2016 Status changed from not yet recruiting to recruiting.
- 28 Sep 2016 New trial record
- 14 Sep 2016 Planned initiation date changed from 1 Aug 2016 to 1 Oct 2016.